Health Catalyst Inc

Health Catalyst Inc(HCAT)の株式分析

$1.590

0.000 (0.00%)終値時点

Loading chart…
High
1.640
Open
1.590
VWAP
1.60
Vol
207.30K
Mkt Cap
357.16M
Low
1.585
Amount
332.71K
EV/EBITDA, TTM
6.11

Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.

AI analysis of Health Catalyst Inc (HCAT)

sell

Health Catalyst Inc is not a good buy right now due to its declining financial performance and negative market sentiment. The current price is $1.59, which is significantly below the analyst price target of $1.80. Additionally, the stock has a low RSI of 33.129, indicating it is oversold, but this does not outweigh the risks of continued losses, as evidenced by a staggering net income loss of $111 million in Q1 2026. The main risk is the insider selling, which has increased by 869.22% over the last month, signaling a lack of confidence from those closest to the company.

バリュエーション指標

The current forward P/E ratio for Health Catalyst Inc (HCAT) is 7.76, compared to its 5-year average forward P/E of -11.88.

Forward P/E

Fair
5Y Average P/E
-11.88
Current P/E
7.76
割高
100.42
割安
-124.18

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-61.88
Current EV/EBITDA
6.11
割高
92.47
割安
-216.24

Forward P/S

Fair
5Y Average P/S
2.18
Current P/S
0.58
割高
4.36
割安
0.00

Alphio AI Price Scenarios for HCAT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%HCAT

$4.94

シナリオ価格

B

Base

Base · 50%HCAT

$4.25

シナリオ価格

B

Bear

Bear · 25%HCAT

$4.22

シナリオ価格

イベントタイムライン

2026-08-06 (ET)

17:30:00

Health Catalyst Closes Sale of Vitalware for $147 Million

17:00:00

Sees Q3 Adjusted EBITDA of $0-$500K

17:00:00

Sees FY26 Adjusted EBITDA of $18M to $18.5M

17:00:00

Company Reports Q2 Revenue of $70.49M, Exceeding Expectations

2026-06-04 (ET)

09:10:00

Health Catalyst Divests Vitalware to Med-Metrix for $147M

ニュース

HCAT FAQ — answered by Alphio AI

Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements. It operates in the Technology sector (SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ET industry).

Health Catalyst Inc is not a good buy right now due to its declining financial performance and negative market sentiment. The current price is $1.59, which is significantly below the analyst price target of $1.80. Additionally, the stock has a low RSI of 33.129, indicating it is oversold, but this does not outweigh the risks of continued losses, as evidenced by a staggering net income loss of $111 million in Q1 2026. The main risk is the insider selling, which has increased by 869.22% over the last month, signaling a lack of confidence from those closest to the company.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める